Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients

Ren Fail. 2007;29(3):321-9. doi: 10.1080/08860220601184092.

Abstract

Aims/hypothesis: It was suggested that polyunsaturated n-3 fatty acids (n-3 PUFAs) could improve insulin sensitivity and have an anti-inflammatory effects in overall population. This study investigates a possible effect of n-3 PUFAs supplementation on the insulin sensitivity and some inflammatory markers; hence, patients with chronic renal failure (CRF) on maintenance hemodialysis (MHD) are presented with insulin resistance.

Methods: This study explored the ratio between red blood cells (RBC) phospholipid long chain fatty acids (LC FAs) and components of metabolic syndrome (MeS) in 35 patients (mean age 54.50 +/- 11.99 years) with CRF on MHD. Furthermore, the effects of omega-3 FA eight-week's supplementation (EPA+DHA, 2.4 g/d) on the MeS features and inflammatory markers TNF-alpha, IL 6, and hsCRP were examined.

Results: Supplementation increased EPA and DHA levels in RBCs (p = 0.009 for EPA and p = 0.002 for DHA). Total n-6 PUFAs: n-3 PUFAs ratio tended to be lower after supplementation (p = 0.31), but not significantly. Data revealed a significant decrease of saturated FAs (SFA) (p = 0.01) as well as total SFA: n-3 PUFAs ratio during the treatment (p = 0.04). The values of serum insulin and calculated IR index-IR HOMA were reduced after supplementation (p = 0.001 for both). There was a significant decrease in the levels of all inflammatory markers (p = 0.01 for TNF alpha, p = 0.001 for IL 6, p = 0.001 for hsCRP, and p = 0.01 for ferritin). In multivariate regression analysis, only the changes in n-6 PUFAs: n-3 PUFAs ratio independently contributed to 40% of the variance in IR HOMA. The impact of changes in PUFAs level in RBCs membrane phospholipid fatty acids on inflammation markers was also registered. The changes in n-6: n-3 PUFAs ratio independently contributed to 18% of the variance in TNF alpha.

Conclusion: It was concluded that the EPA and DHA moderate dose administration in the patients with CRF on MHD had a beneficial effect on insulin resistance decrease. The anti-inflammatory effects of the supplemented PUFAs were also presented.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • C-Reactive Protein / drug effects
  • C-Reactive Protein / metabolism
  • Cross-Sectional Studies
  • Dietary Supplements*
  • Erythrocyte Membrane / drug effects
  • Erythrocyte Membrane / metabolism
  • Fatty Acids, Omega-3 / pharmacology*
  • Fatty Acids, Omega-6 / pharmacology
  • Female
  • Ferritins / blood
  • Ferritins / drug effects
  • Follow-Up Studies
  • Humans
  • Inflammation Mediators / blood*
  • Insulin / blood
  • Insulin Resistance*
  • Interleukin-6 / blood
  • Kidney Failure, Chronic / diet therapy
  • Kidney Failure, Chronic / metabolism*
  • Linear Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Renal Dialysis*
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / blood
  • Tumor Necrosis Factor-alpha / drug effects
  • Yugoslavia

Substances

  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • Inflammation Mediators
  • Insulin
  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Ferritins